ECONOMIC IMPACT OF TREATMENT ADHERENCE IN EXOCRINE PANCREATIC INSUFFICIENCY (EPI) PATIENTS TREATED WITH PANCREATIC ENZYME REPLACEMENT THERAPY (PERT)
Author(s)
Khandelwal N1, Wang S1, Johns B1, Vora J1, Castelli-Haley J1, Singh VK2
1Abbvie Inc, METTAWA, IL, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA
OBJECTIVES : Examine adherence to PERT medications among patients with EPI due to chronic pancreatitis (CP), pancreatic cancer (PC) and pancreatectomy (PY) and investigate the associated healthcare utilization and costs. METHODS : A retrospective analysis was conducted using Truven MarketScan commercial claims data from January 1, 2006 to September 30, 2016. Patients who have at least one diagnosis claim for CP (ICD-9 codes 557.1x, 577.2x, 577.8x), PC (ICD-9 code 157.xx, 230.9x) or PY (CPT codes 48105, 48120, 48140, 48145, 48146, 48148, 48150, 48152, 48153, 48154, 48160), or the corresponding ICD 10 codes and who filled >
Conference/Value in Health Info
2018-05, ISPOR 2018, Baltimore, MD, USA
Value in Health, Vol. 21, S1 (May 2018)
Code
PGI24
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Gastrointestinal Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now